Skip to content

PRECISION GRX Registry

A Multicenter Post-Market Registry for the Evaluation of the CorPath® GRX System Effectiveness in Percutaneous Coronary Interventions

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03278301
Enrollment
952
Registered
2017-09-11
Start date
2017-08-27
Completion date
2020-02-06
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath GRX System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.

Detailed description

This is a single-arm, open-label, multi-center patient registry of the CorPath GRX System to examine its performance during PCI procedures and patient outcomes through 72 hours post-procedure or hospital discharge, whichever occurs first.

Interventions

The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.

Sponsors

Corindus Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Candidates will be included in the study only if all of the following conditions are met: 1. Age ≥18 years; 2. Patients with coronary artery disease with clinical indication for PCI; 3. Patient deemed appropriate for robotic-assisted PCI; and 4. The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

* Candidates will be excluded from the study if any of the following conditions are present: 1. Failure/inability/unwillingness to provide informed consent; or 2. The investigator determines that the patient or the coronary anatomy is not suitable for robotic-assisted PCI.

Design outcomes

Primary

MeasureTime frameDescription
Clinical SuccessDischarge or 72 hours post intervention, whichever comes first.Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the CorPath GRX System, without in-hospital major adverse coronary events (MACE).
Technical SuccessProcedureDefined as successful completion of the robotic-assisted PCI absent unplanned conversion to manual for guidewire or balloon/stent catheter inability to navigate vessel anatomy or poor guide catheter support.

Secondary

MeasureTime frameDescription
Overall Procedure TimeProcedureDefined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.
PCI Procedure TimeProcedureDefined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.
Fluoroscopy TimeProcedureTotal Fluoroscopy Time during procedure will be captured.
Patient Radiation ExposureProcedureDAP (dose-area-product) and cumulative dose/air kerma as recorded during the procedure.

Countries

Brazil, India, Singapore, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026